Single administration of MORAb-202 (5mg/kg) on high FRA-expressing TNBC PDX models showed long-lasting complete tumor regression (4/8), while near-MTD dose of eribulin (3.2mg/kg) showed minimum relative tumor volume of 96%. One dose of MORAb-202 (5mg/kg) elicits partial responses even ...
Cell Lines and Reagents ER-positive/HER2-negative breast cancer cell lines MCF7 and T47D, ER-positive/HER2- positive breast cancer cell lines MDA-MB-361 and SKBR3, ER-negative/HER2-positive breast cancer cell line HCC1954, and TNBC cell lines MDA-MB-231 and BT549 were purchased from ...
In vivo anti‐tumor efficacy studies of MORAb2 were conducted with a single administration of MORAb2 in triple‐negative breast cancer (TNBC) patientヾerived xenograft (PDx) models expressing low and high levels of FRA. MORAb2 exhibited durable efficacy proportional to tumor FRA expression. ...
In the Dose-Escalation phase, the primary objectives were to evaluate safety/tolerability and determine the recommended phase 2 dose of MORAb-202 in patients with OC, endometrial cancer (EC), non-small cell lung cancer (NSCLC), or triple-negative breast cancer (TNBC). In the ongoing Dose-...